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Abstract 
 
Background  
Globally there are several operational definitions for sarcopenia, complicating 
clinical and research applications.  
 
Aim 
The aim of the Australian and New Zealand Society for Sarcopenia and Frailty 
Research (ANZSSFR) Task Force on Diagnostic Criteria for Sarcopenia was to reach 
consensus on the operational definition of sarcopenia for regional use by clinicians 
and researchers.  
 
Method 
A four-Phase modified Delphi process was undertaken in which 24 individuals with 
expertise or a recognised interest in sarcopenia from different fields across Australia 
and New Zealand were invited to be Task Force members. An initial face-to-face 
meeting was held in Adelaide, South Australia, in November 2017, followed by two 
subsequent online Phases conducted by electronic surveys. A final Phase was used to 
approve the final statements. Responses were analysed using a pre-specified 
strategy. The level of agreement required for consensus was 80%.  
 
Results  
In Phase 2, 94.1% of Task Force respondents voted in favour of adopting an existing 
operational definition of sarcopenia. In Phase 3, 94.4% of respondents voted in 
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favour of adopting the European Working Group on Sarcopenia in Older People 
(EWGSOP) definition as the operational definition for sarcopenia in Australia and 
New Zealand. 
 
Conclusion   
With consensus achieved, the ANZSSFR will adopt, promote and validate the 
EWGSOP operational definition of sarcopenia for use by clinicians and researchers in 
Australia and New Zealand.  
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Introduction  
Sarcopenia is defined as an age-related disease of low muscle mass and low muscle 
strength or function [1]. Sarcopenia is of increasing clinical importance due to 
growing evidence of its health implications and the increasing proportion of older 
people in the population. Sarcopenia has been associated with an increased risk and 
rate of falls [2], fractures [3], functional impairment [2], metabolic syndrome [4], 
hospital admission and readmission [2], [5] poorer prognosis in cancer [6] and liver 
cirrhosis [7], surgical morbidity [8] and all-cause mortality [2], [6]. The clinical 
significance of sarcopenia as a distinct disease entity was established with the 
assignment of an International Classification of Diseases, Tenth Revision, Clinical 
Modification (ICD-10-CM) code (M62.84) in September 2016 [9]. 
 
A 2017 systematic review and meta-analysis including 35 studies with 58,404 
individuals estimated that the prevalence of sarcopenia globally was 10% in both 
men and women, and higher among non-Asian than Asian individuals [10]. Others 
have reported the prevalence of sarcopenia to range from 1-29% in community-
dwelling populations, 14-33% in long-term care populations and 10% in acute 
hospital settings [11]. This marked heterogeneity is largely due to the different 
definitions applied to diagnose sarcopenia [12]. Nevertheless, as the global 
population ages, the number of sarcopenic older adults is projected to increase 
substantially over the coming decades. As such, research is needed to help alleviate 
the burden of sarcopenia. For this to be effective, a clear consensus of what defines 
sarcopenia needs to be established. 
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Several operational definitions of sarcopenia have been developed [1], [13] - [17] 
since the term was first coined almost 30 years ago [18]. The most widely used 
operational definitions, combining both low muscle mass and function, are described 
in Appendix 1. While there is widespread agreement on sarcopenia as a disease 
entity, there is no uniform consensus regarding the operational definition of 
sarcopenia. This leads to challenges in comparing results from research studies 
utilising different definitions of sarcopenia, and undoubtedly is a source of confusion 
for both researchers and clinicians. Indeed, only one in five health care professionals 
know how to diagnose sarcopenia using the operational definitions available [19]. 
 
The most widely utilised consensus definition of sarcopenia in the research literature 
was developed by the European Working Group on Sarcopenia in Older People 
(EWGSOP) in 2010 [1]. The EWGSOP definition includes an algorithm comprising gait 
speed, handgrip strength and muscle mass with cut-points dependent upon the 
individual’s demographics (sex and height) [1]. In 2014, this definition was modified 
and validated by the Asian Working Group on Sarcopenia in recognition of the 
impact ethnic differences have on cut-points for muscle mass, strength and 
performance [18]. 
 
The establishment of a demographically-appropriate operational definition of 
sarcopenia is required to unify researchers and provide clear guidance to clinicians 
for the diagnosis and treatment of sarcopenia [20]. A group of individuals with an 
interest or expertise in sarcopenia were invited to join a Task Force and participate 
in a consensus-building collaboration with the aim of establishing an operational 
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definition of sarcopenia for use by researchers and clinicians in Australia and New 
Zealand.  
 
Methods  
A four-Phase modified Delphi method was employed to achieve consensus amongst 
Task Force members on the preferred operational definition of sarcopenia for use in 
Australia and New Zealand (Figure 1). The Delphi method supports the structuring of 
group communication to allow a group of individuals to, as a collective, deal with 
complex problems and reach consensus [21]. The modified Delphi method [22] 
employed by the Task Force allowed for face-to-face communication in Phase 1 and 
approval of final statements in Phase 4. The Task Force leaders (GD, DS, JZ) designed 
and modified the questionnaires in Phases 2 and 3. The modified Delphi method 
used by the Australian and New Zealand Society for Sarcopenia and Frailty Research 
(ANZSSFR) Task Force adhered to preferred reporting methods and procedures [23]. 
 
Selection of Task Force members  
A group of individuals with an interest or expertise in sarcopenia (physicians, 
geriatricians, primary and post-doctoral researchers, allied health professionals, 
health service managers) were invited to participate in a focus group discussion and 
form a Task Force to achieve consensus on the operational definition of sarcopenia 
in Australia and New Zealand. Prior to the first meeting, participants were provided 
with an overview, background, aims, strategies and 17 key references related to the 
different operational definitions of sarcopenia (Appendix 2).  
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Phase 1 – Face-to-face meeting  
On November 26th, 2017 following the ANZSSFR Scientific Meeting in Adelaide, 
Australia, 19 of the 24 invited Task Force members met for a four-hour meeting. Two 
presentations were delivered by researchers to the Task Force (DS and EMR) who 
summarised the key issues and outlined the agenda. Two focus groups were formed 
with key discussion points including whether the Task Force should adopt an existing 
definition or establish a new definition of sarcopenia, and to identify knowledge gaps 
in sarcopenia research. The de-identified minutes of the meeting are attached as 
Appendix 3 and informed the Second Round Questionnaire (2RQ).  
 
Phase 2 – Online Questionnaire  
On December 20th, 2017 an online, anonymous questionnaire (2RQ) developed by 
GD, DS and JZ was circulated to 23 Task Force members. The minutes of Phase 1 
were provided to Task Force members. The pre-specified level of agreement (80%) 
required for consensus was selected by the Task Force Leaders based on 
recommended practice [24], [25] and comparable modified Delphi studies [26]. The 
methodology was outlined to Task Force members who were given three weeks to 
complete the 2RQ. A total of 12 questions and statements were contained in the 
2RQ, which included four statements or key questions, four demographic questions 
and four free-text questions, attached as Appendix 4. The findings of the 2RQ 
informed the development of the Third Round Questionnaire (3RQ).  
 
Phase 3 – Online Questionnaire  
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On February 26th, 2018 an online, anonymous questionnaire (3RQ) informed by the 
2RQ and developed by GD, DS and JZ was circulated to 24 Task Force members who 
were given three weeks to complete the 3RQ. The results of the 2RQ were provided 
verbatim to Task Force members. A total of three statements and questions and four 
demographic questions were included in the 3RQ (Appendix 5).  
 
Phase 4 – Circulation of position paper 
The results of the 3RQ were provided verbatim to Task Force members. The 
statements and questions accepted to the pre-specified level of agreement in Phases 
2 and 3 were circulated amongst Task Force members. Task Force members were 
requested to vote on a single statement contained within the position paper. 
 
Statistical Analysis  
Statistical analysis was undertaken using the pre-specified level of agreement (>80%) 
required to accept a statement. Statements or questions that did not reach a level of 
agreement greater than 80% but achieved moderate agreement (70-80%) in 2RQ 
were re-examined in 3RQ, consistent with comparable modified Delphi 
methodologies [26]. Due to the size of the Task Force in addition to the small 
number of questions and statements being examined, investigation of dispersion or 
heterogeneity was not undertaken as is often performed in larger modified Delphi 
method studies [26]. 
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Results  
A total of 19/24 Task Force members participated in Phase 1. Due to one drop-out 
from Phase 1, 23 Task Force members were surveyed in Phase 2. In Phase 3, 24 
individuals were surveyed following the re-joining of a Task Force member. 
Response rates in Phases 2 (n=17, 73.9%) and 3 (n=18, 75.0%) were similar. Due to 
de-identification, it is unknown whether there was consistency in responding Task 
Force members in Phases 2 and 3. The demographic details of participating Task 
Force members in Phases 2 and 3 are illustrated in Table 1.   
 
In total, two statements regarding the operational definition of sarcopenia were 
accepted to a level greater than 80% and five were rejected (28.6% acceptance rate). 
Questions, statements and respective levels of agreement in each Phase are listed in 
Table 2. In Phase 2, 94.1% of respondents agreed that “an existing operational 
definition for sarcopenia should be adopted and validated using existing Australian 
and New Zealand data sets.” Agreement on a preferred definition of sarcopenia was 
moderate in Phase 2, with 70.6% of respondents supporting the EWGSOP definition 
[1], 17.6% supporting the Foundation for the National Institute of Health Biomarkers 
Consortium Sarcopenia Project (FNIH) definition [16], and 11.8% supporting other 
[13] or new definitions. Consensus was not achieved (76.5%) on the adoption and 
promotion of the sarcopenia screening tool, SARC-F [27], for use by primary care 
clinicians. 
 
In Phase 3, 94.4% of respondents agreed to adopt the EWGSOP operational 
definition of sarcopenia. Consensus was not achieved on whether the ANZSSFR 
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should adopt and promote the accepted operational definition in its current form, 
including established cut-points, or await validation studies among Australian and 
New Zealand populations. There was moderate agreement (72.2%) amongst 
respondents that an established definition should be adopted and promoted 
immediately, with cut-points for sarcopenia components (e.g. muscle mass, muscle 
strength and gait speed) modified should future validation studies suggest this is 
necessary for Australian and New Zealand populations. Conversely, 22.2% of 
respondents agreed that the promotion of an established definition should await 
validation studies, while 5.6% of respondents agreed that an existing definition 
including cut-points should be adopted and promoted in its entirety without need 
for further validation among Australian and New Zealand populations. 
 
In Phase 4, Task Force members were presented with a position paper and surveyed 
on their agreement with the statement posed in 3RQ, that the ANZSSFR should 
adopt and promote the EWGSOP and its established cut-points and modify these 
cut-points if validation studies suggest this as necessary. There was 100% agreement 
from 23 respondents to this statement.  
 
Discussion  
To date, a definition of sarcopenia has not been specifically developed for, or 
validated in, Australian and New Zealand populations. Across the globe, 
demographic differences have resulted in various measurement cut-points [17], 
therefore the ANZSSFR Task Force on Sarcopenia was formed to achieve consensus 
on an operational definition of sarcopenia for use by researchers and clinicians in 
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Australia and New Zealand. Leading researchers in sarcopenia have called for a 
consensus definition [20], a sentiment echoed in Phase 1 of the Delphi method 
undertaken by the Task Force. Task Force members achieved consensus in Phase 2 of 
the Delphi method to adopt and validate an existing definition of sarcopenia, rather 
than develop a new definition in Australia and New Zealand. The consensus to adopt 
the EWGSOP operational definition of sarcopenia reflects the fact that this is 
currently the most cited definition of sarcopenia worldwide [1]. 
 
While consensus was achieved on the adoption of the EWGSOP operational 
definition of sarcopenia, the timing of when to promote the definition fell short of 
the pre-specified level of agreement in Phase 3. A majority of respondents (72.2%) in 
Phase 3 agreed that the EWGSOP definition should be promoted immediately and 
subsequent validation studies should determine whether diagnostic cut-points need 
to be modified. Consensus on this statement was achieved in Phase 4 with 
agreement of 100%. Therefore the ANZSSFR Task Force have achieved consensus for 
the immediate promotion of the EWGSOP definition in its activities directed at 
researchers and clinicians. A key objective for the Task Force will be to determine 
whether appropriate cut-points for muscle mass, handgrip strength and gait speed 
can be established using data from local cohort studies if the EWGSOP cut-points are 
found not to be predictive of sarcopenia-related outcomes in Australian and New 
Zealand older adult populations [1]. Australia and New Zealand are comprised of 
ethnically diverse, indigenous and immigrant populations to whom existing 
sarcopenia definitions and cut-points may not apply. The Asian Working Group on 
Sarcopenia previously adopted modified cut-points for the EWGSOP definition 
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reflective of differences in muscle mass and strength observed between Asian and 
European older adults [18]. Our Task Force will also promote sarcopenia research in 
Australia and New Zealand’s diverse populations to determine whether different cut-
points are required in different ethnic groups within our countries. Further, if these 
validation studies or further research in sarcopenia suggest other measures of 
muscle mass, muscle strength and physical performance are superior to those 
adopted, additional examination of the definition by the Task Force may be required.  
 
In clinical practice, diagnostic tools such as dual energy X-ray absorptiometry (DXA), 
bioimpedance analysis (BIA) and handgrip strength dynamometers may not be 
immediately available to the clinician. A screening tool for sarcopenia, SARC-F, was 
developed for use by clinicians and was found to be valid for predicting adverse 
outcomes in sarcopenia [27]. A recent meta-analysis demonstrated that the SARC-F 
had poor sensitivity but high specificity for predicting those that should undergo 
further diagnostic testing for sarcopenia [28]. While the majority (61.1%) of 
respondents reported a decision should be made on the use of SARC-F following 
further research, only 33.3% supported the immediate adoption and promotion of 
this tool for use as a screening device in the Australia and New Zealand. Therefore, 
the Task Force will advocate for further research on SARC-F in Australia and New 
Zealand and re-evaluate support for the SARC-F as a screening tool in the future.  
 
A Delphi method may be limited by the breadth and diversity of its participants and 
rate of responses. In this modified Delphi method, a broad range of Task Force 
members across Australia and New Zealand were involved, however this process was 
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limited by low or no representation from some Australian states. This Delphi method 
was strengthened by response rates in Phases 2, 3 and 4 exceeding 70% and the 
release of results verbatim to Task Force members. While preference exists for the 
involvement of patients or consumers in a Delphi method [23], the complexity and 
depth of knowledge required to judiciously answer questions and statements 
required experts in the field of sarcopenia, particularly given the low levels of public 
awareness of sarcopenia. Nevertheless, future activities for this Task Force will seek 
to engage clinicians and consumers. 
 
The development of this consensus definition has the potential to unify researchers 
across Australia and New Zealand and assist with further international collaborations. 
In addition, the provision of a consistent definition and message to primary care 
clinicians and the aged care and long-term care sectors, where prevalence is at its 
highest, may increase diagnosis and treatment of sarcopenia.  
 
Conclusion 
The ANZSSFR will adopt and promote the EWGSOP operational definition of 
sarcopenia in Australia and New Zealand however the ANZSSFR acknowledges 
further research is required to validate the definition in this setting. This is a 
significant step towards regional and international consensus on sarcopenia in the 
understanding of this disease. Validation studies will be undertaken using this 
definition among specific regional and ethnic populations, and may result in future 
recommendations which provide adapted cut-points for individual components of 
sarcopenia. Any future variations to the current EWGSOP definition will be 
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considered and evaluated by the ANZSSFR Task Force prior to adoption and 
validation.  
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Figure 1. Flow Chart of modified Delphi Method  
 
 
ANZSSFR  - Australian and New Zealand Society for Sarcopenia and Frailty Research. 
2RQ – Second-round Questionnaire.  3RQ – Third-round Questionnaire. n = number 
of respondents 
  
Finalisation of Position Statement (n = 24) 
Phase 4: Development and circulation of final statements
Sent to Task Force May 2018
Analysis of 3RQ (n = 18) 
Phase 3: Design and circulation of 3RQ
Sent to Task Force 26th February 2018
Analysis of 2RQ (n =17) 
Phase 2: Design and circulation of 2RQ 
Sent to Task Force 20th December 2017
Phase 1: Face-to-face meeting at ANZSSFR conference - November 2017
Two Focus Group Discussions Identification of questions and statements
Bibliography sent to Task Force - November 2017 
Invitation to join ANZSSFR Task Force - September 2017
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Table 1. Demographics of Task Force members in Phases 2 and 3 
 
Variable  Phase 2 (n = 17) Phase 3 (n = 18) 
Mean age, years (SD)  42.5 (10.3) 44.2 (10.2) 
Gender, n (Female, %) 5 (29.4%) 6 (33.3%) 
State or Country (n)  
  New South Wales 
Victoria 
Queensland 
South Australia 
Western Australia 
New Zealand  
 
1 
10 
1 
2 
1 
1 
 
1 
10 
1 
2 
3 
1 
Position or Role (n)  
Primary clinical researcher 
Post-doctoral researcher 
Physician/geriatrician 
Allied health  
Health service manager 
 
7 
2 
5 
1 
2 
 
10 
2 
4 
1 
1 
SD = Standard Deviation 
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Table 2.   Non-free text questions, statements and respective levels of agreement  
 
Questions and Statements Respondents, n (% of invitation) Agreement (%) Outcome 
Phase 2 
5. An existing operational definition for sarcopenia should be adopted and 
validated using existing Australian and New Zealand data sets 
17 (73.9%) 94.1% Accepted 
6. If the adoption of an existing definition is the majority opinion of the Task 
Force, which operational definition of sarcopenia do you prefer? 
 EWGSOP  
 FNIH  
 Other  
 
 
12 (52.2%) 
3 (13.0%) 
2 (8.7%) 
 
 
70.6% 
17.7% 
11.8% 
 
 
Informed 3RQ 
8. If the ANZSSFR proposes to develop a new definition with Aus./NZ data on the 
basis of these survey results, please provide suggestions for the proposed 
methodology (eg. Measurement tools; cut-points etc.). 
 I do not support an additional definition therefore do not wish to comment 
 Preferred methodology / cut-points 
 
 
 
9 (39.2%) 
8 (34.8%) 
 
 
 
52.9% 
47.1% 
 
 
 
Rejected 
9. Should the society consider recommending the SARC-F as a screening tool for 
GPs, allied health and other health professionals? 
 Yes 
 No 
 
 
13 (56.5%) 
4 (17.4%) 
 
 
76.5% 
23.5% 
 
 
Informed 3RQ 
Phase 3 
5. Which operational definition of sarcopenia should the ANZSSFR adopt? 
 EWGSOP  
 FNIH 
 
17 (70.1%) 
1 (4.2%) 
 
94.4% 
5.6% 
 
Accepted 
EWGSOP 
6. The ANZSSFR should; 
 Adopt and promote an established definition in its entirety (including its 
existing cut-points) 
 Adopt and promote an established definition and modify this in future if 
subsequent validation studies suggest different cut-points are more 
appropriate in Australia and New Zealand 
 Await the validation studies of Aus./NZ cohorts prior to adopting and 
promoting a definition 
 
1 (4.2%) 
 
13 (54.2%) 
 
 
4 (16.7%) 
 
5.6% 
 
72.2% 
 
 
22.2% 
 
 
 
Informed Phase 
4 
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7. The pre-specified level of agreement (80%) was not reached to adopt the SARC-
F as a recommendation for a screening tool for GPs and other allied health 
professionals (77%). To further explore this question, should the ANZSSFR; 
 Recommend the SARC-F as a screening tool for GPs, allied health and other 
health professionals at the present time 
 Not include SARC-F in its recommendations at the present time 
 Consider SARC-F in the future when consensus is achieved on the preferred 
operational definition of sarcopenia, and research is undertaken to 
demonstrate that SARC-F is an acceptable screening tool in Aus./NZ 
 
 
 
6 (25%) 
 
1 (94.2%) 
11 (45.8%) 
 
 
 
33.3% 
 
5.6% 
61.1% 
 
 
 
 
 
 
Rejected 
Phase 4 
1. The ANZSSFR Task Force should promote the EWGSOP definition in our 
activities directed at clinicians and researchers. However, a key objective for the 
Task Force in future will be to establish appropriate cut-points for appendicular 
lean muscle mass, handgrip strength and gait speed in Australian and New 
Zealand populations using data from local cohort studies. 
23 (95.8%) 100.0% Accepted 
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Appendix 1. Different Operational Definitions of Sarcopenia  
 
Component Cut-points 
European Working Group on Sarcopenia in Older People [1] 
Low muscle mass 
 
 
 
 
 
 
Low muscle strength 
 
 
 
Poor physical performance 
ALM adjusted for height (m2) using whole-body DXA 
Men: <7.26kg/m2 
Women: <5.50kg/m2 
SMM adjusted for height (m2) using BIA 
Men: <8.87kg/m2 
Women: <6.42kg/m2 
 
Hand grip strength using dynamometer 
Men: <30kg  
Women: < 20kg 
 
Gait speed: ≤ 0.8m/s 
International Working Group on Sarcopenia [2] 
Low muscle mass 
 
 
 
Poor physical performance 
ALM adjusted for height (m2) using whole-body DXA 
Men: <7.23kg/m2 
Women: <5.67kg/m2 
 
Gait speed:  < 1.0m/s 
Society of Sarcopenia, Cachexia and Wasting Disorders [3] 
Low muscle mass 
 
 
 
Poor physical performance 
ALM adjusted for height (m2) using whole-body DXA  
< 2 SD less than healthy person between age 20 and 
30 years of the same ethnic group 
 
Gait speed: < 1.0 m/s or < 400m in 6-minute walk 
test 
Foundation for the National Institutes of Health [4]  
Low muscle mass 
 
 
 
Low muscle strength 
ALM adjusted for BMI (kg/m2) using whole-body DXA 
Men: <0.789 
Women: <0.512 
 
Hand grip strength using dynamometer 
Men:  <26kg 
Women: <16kg 
Asian Working Group on Sarcopenia [5] 
Low muscle mass 
 
 
 
 
 
 
 
Low muscle strength 
ALM adjusted for height (m2) using whole-body DXA 
Men: <7.0cm2/m2 
Women: <5.4cm2/m2 
 
SMM adjusted for height (m2) using BIA 
Men: <7.0cm2/m2 
Women: <5.7cm2/m2 
 
Hand grip strength using dynamometer 
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Poor physical performance 
Men:  <26kg 
Women: <18kg 
 
Gait speed: ≤ 0.8m/s 
ALM = Appendicular lean mass. DXA = Dual X-Ray Absorptiometry. BIA = Bioimpedence 
Analysis. SMM = Skeletal Muscle Mass. BMI = Body Mass Index. SD = Standard Deviation 
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Appendix 3. Minutes from Phase 1 Face-to-Face Meeting in Adelaide 
 
 
Minutes ANZSSFR Task Force Meeting on Diagnostic Criteria for Sarcopenia. 
Sunday November 26th, Adelaide Health and Medical Sciences Building, North Terrace, 
Adelaide. 
Present: De-identified  
Apologies: De-identified 
 
The primary aim for this Task Force is to determine a single operational definition of 
sarcopenia for promotion to clinicians and researchers in Australia and New Zealand. We 
believe this may be achieved through one of the two following strategies:  
 
1. Adoption of an existing international operational definition, measurements and 
cut-points with research activities including validation of cut-points within Australian 
older adult cohorts.  
2. Development of a new Australian and New Zealand operational definition, 
measurements or cut-points, the methods for which may or may not be informed by 
existing international definitions.  
 
Task Force Members will be invited to discuss these potential (and other strategies) and, if a 
preference is agreed upon, to engage in associated research activities.  
 
Key Discussion Points  
 
• Do we need a single operational definition of sarcopenia for Australian and New 
Zealand researchers/clinicians?  
• If so, do we support an existing international operational definition (Strategy 1) or 
believe a definition specific to Australia and New Zealand is needed (Strategy 2  
 
Mediator: De-identified: definition of sarcopenia – research setting 
 
Strategy 1: If we are to support an existing operational definition, which should it 
be? What are the strengths and weaknesses of existing definitions? How do we 
validate an existing international definition in Australia?  
Strategy 2: What work is needed to develop a local operational definition?  
 
What measurements are appropriate and what data is available to support this?  
There is a challenge in achieving a single “operational Definition” for Sarcopenia. There is 
not an Aust/ NZ definition for sarcopenia 
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NHMRC – comments often came back that we used the wrong definition 
To facilitate research and funding 
Develop a white paper to publish is JAMDA 
Following the definition there were more publications 
• RASM (ht2) 
• Janssen – normalized by weight 
Need consider muscle mass v function 
Mass decreases less than function 
Dynapenia – Ended up with mass as well as function 
EWGSOP – most use this but was meant to be a suggestion 
FNIH definition has slightly stricter approach – but may miss a lot of people 
<0.8m/sec 
FNIH2: Are saying grip strength normalized to BMI is the most suitable 
SARC-F – screening tool (first three questions had greatest AUC) 
SPRINNT Trial – combines sarcopenia and frailty definitions 
ICD-10-CM: Assignment in 2016.  
What is the end point of sarcopenia? 
Gait speed?Falls/fractures? Quality of Life? 
There is a little overlap in definitions 
Assessing muscle mass: DXA v BIA 
Differences in ALM controlled for height v BMI 
Which is the best indicator of function? 
Handgrip strength, gait speed, power?, muscle quality 
Muscle wasting v age related sarcopenia 
Primary (age-related only) v secondary (bed rest, nutrition) 
 
Strategies : Adopt a current cut off? 
Develop our own? Other? 
 
Group discussion 
Is it a problem? 
Do we adopt or re-invent? 
Sarcopenia definition – is it a definition? 
Need an easy tool for diagnosis.  
Do we only need one definition? 
One definition – clear cut off 
Similar one that we can compare to other countries 
How do we define the cut off – 2SD below young adults, what do we use as the cut off? 
Is function the main outcome? 
A single operation would be advantageous 
Adopting international measures. 
Do we need an outcome to work towards to define sarcopenia or the EWGSOP have it in 
their definition? 
Align to an international criteria. 
 
Delphi process to get the best definition (evidence based) and that is put forward to use. 
Validate the definition in our longitudinal studies 
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Maybe have a research definition then a clinical definition 
The Delphi process can commence with the task force in a step-wise methodology.  
The clinical definition needs to have all the key stake holders involved. 
We have international advisors to assist in the process. 
Diagnostic criteria: what do clinicians need 
Overlap in prevalence is very poor across all the different groups 
Frailty and sarcopenia not the same 
EWGSOP – suggest use this definition 
Had a Sarcopenia  road show:   Sarcopenia  pocket card 
 
Group discussion 1  
 
Need single definition to be recognised by clinicians  
Need an outcome, to test the definitions  
Clinician wants an outcome that we are trying to prevent by the diagnosis/treatment. 
Sarcopenia has implications for cardiometabolic disease  
In addition to inflammation/protein storage. We need clarity in the field.  
Receive frequent questions regarding this uncertainty.   
Need definition from two perspectives – clinical and research. If ICD-10 approved, have to 
discuss with Medicare at what rate this diagnosis will be paid etc. If ICD-10 approved, 
government will want to know how to identify sarcopenia in the acute setting.  
Need to establish how to diagnose and what the implications are for making the diagnosis. 
What is the outcome? What is the intervention to change this outcome/treatment of the 
condition.  
Establish difference for acute and chronic/community etc.  
With confusion in the academic literature, this introduces confusion and uncertainty 
amongst GPs.  
We will need our own data to justify the diagnosis.  
Clinicians don't know about grip strength. Even though lower limb strength may be a better 
measure, will be too confusing to introduce new measure  
Seconds concerns regarding introducing new measure (lower limb strength). First step is to 
use/combine existing definitions, and validating this with our own data set.  
Issues with gait speed seconded.  
FNIH 2 – will be pushing on with developing hand grip strength normalized for BMI  
What can you predict with sarcopenia that you cannot predict with gait speed? Do we have 
evidence that sarcopenia predicts something else not predicted by gait speed? No. We need 
to find the gaps in sarcopenia research first. Gait speed may predict falls, sarcopenia can 
predict injury – there are no studies demonstrating this. Delphi process should be utilized in 
developing white/paper  
We should look worldwide for evidence before developing definition in Australia. We should 
think that the Australian population isn’t too different from the rest of the world.  
We need the outcome.  
No longitudinal prospective study designs have been established.  
We have a lot of the data, but no one has looked at it.  
Existing Perth data set over large date range. 1500 in data set.  
We have data from well-designed longitudinal studies, but we haven’t used it.  
FNIH 2 correction of adjustment is statistically problematic  
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Using only clinical parameters results in can result in a lot of confounding, as opposed to 
objective measures. We do need an objective measure in addition to the clinical.  
Useful to have DXA for research, but also gives clues clinically. If there is one adverse 
outcome associated with a specific finding in the DXA, that can inform discussion with policy 
makers.  
Could an injurious fall then meet the definition of sarcopenia?  
Need to prove that there is cost-effectiveness / return of investment on performing 
DXA/investigations.  
 
 
Outcomes  
- Align ourselves with international consensus 
- Utilization of the Delphi process to develop consensus for the society 
o Development of White Paper to answer specific questions (i.e. gait speed in 
Canada)  
o Includes key stakeholders including clinicians, patients, policy makers  
o Benefits include external validity, oral and written feedback  
o Can develop one paper identify the gaps, second paper showing the outcome 
of the Delphi process  
o This Task force is the first part of the Delphi process.  
- We need a key outcome (current gap in the research)  
- Need for consensus on research and clinician definition but not necessarily a new 
definition 
o Reluctance in general for development of an additional definition 
- Existing data sets in Aus./NZ should be utilized to answer gaps in the research – 
connecting diagnosis/syndrome with outcome, to validate existing definitions.  
- Develop statement for the website by February / grant application time 
- Develop paper that identifies the research gaps  
- International advisors 
-  
Group discussion 2   
 
What are the priorities for the ANZSSFR in promoting sarcopenia to clinicians and the public? 
What methods/definitions may be most accessible/relevant to clinicians?  
What activities should we engage in to promote sarcopenia assessment and treatment? Are 
there funding opportunities to support these activities?  
What types of clinicians should be targeted?  
 
- Task force to define the guidelines for priority groups (GPs, geriatricians) in Australia  
o British Geriatric Society has similar frailty guidelines  
o Should have first “success story” – the target group could be the geriatricians  
- Incorporate sarcopenia into medical and allied health curricula (but need “runs on 
the board” first)  
- Development of position statement for the society – 
- Possibility of incorporating the sarcopenia screen into the GP management plan 70+ 
screen? – Medicare Benefit Scheme 
- Need community health promotion campaign  
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o Community prevention and advertising approach 
- Funding  
o General Practitioner grants for Continuing Medical Education  
o Department of Veterans Affairs through the ANZSSFR  
- ANZSGM ASM in June  
o Symposium for perioperative medicine  
- Other societies to target  
o Physio society  
o Rehab meetings 
- Development of new website for society 
 
Consensus on next steps for the Task Force 
1. Develop a societal position on definition of sarcopenia  
a. Adopt existing definition  
2. Delphi process  
a. to commence   
3. White Paper  
a. For development after Delphi Process 
4. Position statement  
a. to develop  
5. Promotional campaign  
a. Health professionals  
b. Public 
6. Analysis of existing Aus./NZ data sets  
a. Definition linking to outcomes  
b. Definition agreements  
7. Amalgamation of Australian data sets  
8. Steps for facilitating communication/discussion  
a. Agreement to meet 2 meetings per year Task Force 
b. Proposal to have further round table discussions in March/April (face-to-face 
and online) 
9. Increase sectorial awareness  
a. Publications in resicare journals  
10. Provision of summary statement for the minister on the societies activities  
 
Tasks  
- Delphi process (to set up agenda for future research) 
o Research definition  
o Clinical definition  
- Development of white paper based (include background from Delphi)  
- Perform analysis of our data sets (Aus./NZ) to demonstrate agreement with current 
definitions, and examine for outcome measures 
- Agreement in the first session and then move to 2 phases with a panel of experts for 
(1) RESEARCH and then (2) Clinical with other stake holders. 
-  
 
Presentation 
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Presentation of Data of the lack of Guidelines for Sarcopenia. For Medical practitioners, 
Dieticians, Nurses and Allied Health professionals who at present are all using different ways 
of diagnosing  Sarcopenia (see attached PDF) 
In Europe the majority of people thought Sarcopenia and how to maintain muscle health 
was through exercise and nutrition. 
Awareness-ageing, physical acts, malnutrition 
Consequences- Falls 
Treatment- motivation is needed 
Obstacles- 75% saw no obstacles. 
SUMMARY OF PRESENTATION: The need for  
One definition 
•Diagnostic tools 
•Sufficient knowledge to diagnose/manage  
•Collaborations between healthcare professionals 
•Funding source (ICD-10) 
 
Additional comments noted 
Definitions can be helpful to improve diagnostic reference 
Need the correct test or definition to have reliability of diagnosis 
First step is to identify the gaps but good to have an initial perspective 
To be an International Advisor and mentor 
To get an Asian Working Group reprepresentative/advisor.to bring to the Research level a 
link which is important to Medical Research Future Funds 
Learning expectations needs to be defined for all disciplines 
Differing levels of diagnostic tools 
?integrate into medical Software 
Pharmacists are useful at providing additional information 
Only 5% of falls are being referred to the right places. 
Can we do earlier screening? 
Discussion on Media exposure. Is needed to increase people’s awareness of the condition 
and then it requires Medical education. At this stage there is nothing in the Media. 
Ageing is on the agenda throughout Europe, but not in Australia and NZ 
The urgent need to place sarcopenia in the teaching/learning and curriculum 
Priorities to target: GP’s pharmacies, RCGP’s send all guidelines through the College to all 
GP’s nationally. 
Suggested an initiative to create a smaller taskforce to define the guidelines in Frailty and 
Sarcopenia, for all GPs in the country. It must be simple. Target the overall population. 
Geriatricians to assess the condition when referred on, but must have GP’s aware in order 
to refer on. Need a success story in Australia. The priority to train and provide GP’s, or 
integrate Sarcopenia into practices, or include in Geriatrician’s curriculum OR target all. 
 
Need pathways and need investment to get into all the pathways. 
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Already have Falls and Fracture clinics, and Gait and Balance. Can Sarcopenia be 
added/integrated into it? 
Curriculum difficult to get into. Sarcopenia needs a profile. ?AJA Journal/Aust Society 
Geriatricians? 
To take initiative on this area 
Short term goals GP’s are crucial to start with. 
Link falls and fractures to muscle and this will profile with Sarcopenia. 
Need to start with a positive statement which gives it more power. 
Need to focus of Sarcopenia and keep Osteoporosis out of it. 
Consensus was that it was better to start the target with Geriatricians and then lead onto 
GP’s 
70+ Screen? Can a screen for Sarcopenia be incorporated into this screening and also Gait 
speed? 
A preventative message needs to be circulated 
Use of work Sarcopenia. Geriatricians keep sending it back to GP’s and then they may 
question ad enquire what it is? 
National Sarcopenia Day? 
 
Funding Questions: 
Issue can be relatively easily funded. Target colleagues for small grants, that is educational 
grants. 
From all tiers of Government and ask all to do some groundwork 
ANZGM ask to incorporate into new social development. Annual Conference in June and will 
be involved. 
? ANZSSFR stand at the Geriatric meeting in June? 
 
Need to target all related Societies and their meetings/conferences 
Website: critical information. Website being established at this time. 
 
AGREEMENT AT THE END OF THIS MEETING. 
1.take position as a society on which definition to recommend with the preference-  
adopting what is already put there. 
2.Delphi process the first step to start 
3. position statement to coincide with public awareness, conferences early/mid 2018 
4.data together with etc. and comparisons made 
5.achieve a conversation on strategies to reach a consensus 
6.invitations for involvement in activities  
7.white paper 
8. cohort synthesis and data analysis 
9. prominent activities 
10. reconvene next ANZSSFR Annual meeting 2018 
11. early meetings March/April; with some smaller meetings of 5-6 people  
 
Ended the meeting and thanked everyone for making the time to attend. Agreed it was a 
most productive exercise  
 
“We want to present a case to the world.” 
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MEETING CONCLUDED AT 12.30PM 
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Appendix 4. Second-round Questionnaire (2RQ) 
 
1. What is your age?  
2. What is your gender? 
3. Please select your state and country  
4. What is your Position / job title /role? 
 
Quantification and confirmation of focus group discussion results  
 
5. Clinical operational definition for sarcopenia.  
Select the statement that reflects your view;  
a. An existing operational definition for sarcopenia should be adopted and 
validated using existing Australian and New Zealand data sets  
b. A new Australian and New Zealand operational definition for sarcopenia should 
be developed using existing Australian and New Zealand data sets  
c. Other – free text.  
6. If the adoption of an existing definition is the majority opinion of the Task Force, 
which operational definition of sarcopenia do you prefer;  
a. European Working Group on Sarcopenia in Older People (EWGSOP)  
b. Foundation for the National Institutes of Health Sarcopenia Project (FNIH)  
c. Other – free text  
7. Please give your reasoning behind your selection in 2 - Free text 
8. If the ANZSSFR proposes to develop a new definition on the basis of these survey 
results, please provide suggestions for the proposed methodology (eg. Measurement 
tools; cut-points etc.). - Free text  
9. The SARC-F is a 5 question self-rated screening questionnaire for sarcopenia.  
Should the society consider recommending the SARC-F as a screening tool for GPs, 
allied health and other health professionals?  
a. Yes  
b. No  
Further comment 
10. Should the ANZSSFR adopt distinct definitions, with one for clinical purposes and one 
for research purposes?  
c. Yes 
d. No 
If you answered a, which definitions should be used for each?  
Free text.  
11. In addition to the establishment of an operational definition, what are the key 
knowledge gaps on which sarcopenia research should focus?  
Free text  
12. Are you interested in contributing further to the development of the White Paper on 
Sarcopenia? (In subsequent phases your email address will be requested).  
- Yes  
- No 
13. Any further comments you wish to make?  
Free text 
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Appendix 5. Third-round Questionnaire (3RQ) 
 
Participant demographic details  
 
1.  What is your age in years? 
2.  What is your gender? 
3.  In which state or country are you based?  
4. What is your job title / role (Physician/Specialty, Researcher, Allied Health Professional, 
other)?  
 
5. Phase II of the Delphi conference of the ANZSSFR Task Force has demonstrated 
agreement (approx. 94%) for the adoption of an existing operational definition for 
sarcopenia in Australia and New Zealand. We now hope to achieve a consensus (80% 
agreement) on which existing operational definition should be adopted.  
Which operational definition of sarcopenia should the ANZSSFR adopt? 
e. European Working Group on Sarcopenia in Older People (EWGSOP)  
f. Foundation for the National Institutes of Health Sarcopenia Project (FNIH)  
 
6. The ANZSSFR Task Force has voted to adopt an established operational definition of 
sarcopenia. However, cut-points for sarcopenia components in existing definitions have 
previously been modified in different geographic locations (for example the Asian Working 
Group on Sarcopenia adopted the EWGSOP algorithm for sarcopenia case-finding but 
applied cut-points that may be more appropriate in Asian populations).  
 
The ANZSSFR Task Force intends to undertake validations studies using the chosen 
definition in Aus./NZ data sets over the next 18 months.  
 
At the present moment, do you think the ANZSSFR should; 
A. Adopt an established definition in its entirety (including existing cut-points) 
B. Adopt and promote an established definition and modify in future if subsequent 
validation studies suggest different cut-points are more appropriate in Australia and 
New Zealand 
C. Await the validation studies of Aus./NZ cohort prior to adopting and promoting a 
definition 
 
Question 7 – The pre-specified level of agreement (80%) was not reached to adopt the 
SARC-F as a recommendation for a screening tool for GPs and other allied health 
professionals (77%). To further explore this question, should the ANZSSFR;  
A. Recommend the SARC-F as a screening tool for GPs, allied health and other health 
professionals at the present time 
B. Not include SARC-F in its recommendations at the present time 
C. Consider SARC-F in the future when consensus is achieved on the preferred 
operational definition of sarcopenia, and research is undertaken to demonstrate that 
SARC-F is an acceptable screening tool in Aus./NZ  
This is a post-peer-review, pre-copyedit version of an article published in The journal of nutrition, health & aging. 
The final authenticated version is available online at: http://dx.doi.org/10.1007%2Fs12603-018-1113-6
 This is a post-peer-review, pre-copyedit version of an article published in The journal of nutrition, health & aging. 
The final authenticated version is available online at: http://dx.doi.org/10.1007%2Fs12603-018-1113-6
